MGMT expression and pituitary tumours: relationship to tumour biology
Over the past half decade, temozolomide, an oral akylating chemotherapeutic agent, has been shown to have significant activity in the management of aggressive pituitary tumours. The expression of 06-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme, is an important predictor of response to therapy. Low MGMT expression has been reported with a higher frequency amongst more aggressive pituitary tumours, suggesting MGMT may play a role in pituitary tumour progression. In this study, we performed a microarray analysis to determine whether there was a distinct gene expression profile between tumours with low MGMT and high MGMT expression. Overall, 1,403 differentially expressed genes were identified with raw p values less than 0.05. Gene set enrichment analysis (GSEA) revealed significant differences in the gene expression profile between high and low MGMT expressing pituitary tumours. High MGMT expressing pituitary tumours were found to have upregulation of components of the FGFR family and downstream signaling cascades such as PI3 K/Akt and MAPK pathways. Activation of genes involved in the DNA damage response and DNA repair pathways, as well as genes involved in transcription, were identified in pituitary tumours with low MGMT expression. These results form the basis of our proposed model to describe the role of MGMT in pituitary tumorigenesis.
|ISBN||1573-7403 (Electronic) 1386-341X (Linking)|
|Authors||McCormack, A. ; Kaplan, W. ; Gill, A. J. ; Little, N. ; Cook, R.; Robinson, B.; Clifton-Bligh, R.;|
|Responsible Garvan Author|
|Published Date||2013-06-01 00:00:00|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/22797801|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/11993|